-
Taxonomy & unit
-
us-gaap: USD
-
Description
-
Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.
-
Summary
-
Zentalis Pharmaceuticals, Inc. quarterly/annual Income Tax Expense (Benefit) history and growth rate from 2019 to 2023.
- Zentalis Pharmaceuticals, Inc. Income Tax Expense (Benefit) for the quarter ending June 30, 2024 was $266K.
- Zentalis Pharmaceuticals, Inc. Income Tax Expense (Benefit) for the twelve months ending June 30, 2024 was $305K.
- Zentalis Pharmaceuticals, Inc. annual Income Tax Expense (Benefit) for 2023 was -$601K, a 28.1% decline from 2022.
- Zentalis Pharmaceuticals, Inc. annual Income Tax Expense (Benefit) for 2022 was -$469K, a 57.9% decline from 2021.
- Zentalis Pharmaceuticals, Inc. annual Income Tax Expense (Benefit) for 2021 was -$297K, a 167% decline from 2020.
Income Tax Expense (Benefit), Trailing 12 Months (USD)
Income Tax Expense (Benefit), Annual (USD)
Income Tax Expense (Benefit), YoY Annual Growth (%)